Rhumbline Advisers Sells 17,892 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Rhumbline Advisers lessened its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 1.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,057,199 shares of the company’s stock after selling 17,892 shares during the quarter. Rhumbline Advisers owned about 0.15% of Roivant Sciences worth $10,667,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Parallel Advisors LLC lifted its position in Roivant Sciences by 80.5% during the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company’s stock valued at $25,000 after purchasing an additional 1,108 shares during the last quarter. Treasurer of the State of North Carolina lifted its holdings in shares of Roivant Sciences by 0.6% during the 4th quarter. Treasurer of the State of North Carolina now owns 187,047 shares of the company’s stock worth $2,213,000 after acquiring an additional 1,170 shares during the last quarter. WINTON GROUP Ltd lifted its holdings in shares of Roivant Sciences by 1.5% during the 4th quarter. WINTON GROUP Ltd now owns 92,526 shares of the company’s stock worth $1,095,000 after acquiring an additional 1,332 shares during the last quarter. Covestor Ltd lifted its stake in Roivant Sciences by 7.5% during the fourth quarter. Covestor Ltd now owns 20,634 shares of the company’s stock worth $245,000 after purchasing an additional 1,444 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after purchasing an additional 1,507 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

ROIV has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Wednesday, May 28th. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th.

Roivant Sciences Stock Down 1.3%

Roivant Sciences stock opened at $11.08 on Tuesday. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $13.06. The firm has a fifty day simple moving average of $10.66 and a two-hundred day simple moving average of $11.00. The company has a market capitalization of $7.91 billion, a PE ratio of -73.86 and a beta of 1.16.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.15). Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. The company had revenue of $7.57 million during the quarter, compared to the consensus estimate of $62.17 million. During the same quarter in the previous year, the firm posted ($0.23) EPS. As a group, equities analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 547,430 shares of the company’s stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $11.34, for a total transaction of $6,207,856.20. Following the completion of the transaction, the insider now owns 38,627,181 shares of the company’s stock, valued at $438,032,232.54. This represents a 1.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $10.22, for a total value of $1,022,000.00. Following the transaction, the chief operating officer now directly owns 1,116,345 shares of the company’s stock, valued at $11,409,045.90. The trade was a 8.22% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,972,189 shares of company stock worth $33,059,785. 7.90% of the stock is currently owned by insiders.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.